APGE PRESS-RELEASE SEC Filing Analysis

Latest settled — T+20d

APGE ▲ +12.43% at T+20d

SHORT call ✗ call lost -12.43% · α vs SPY -4.57% · entry $78.53 → $88.29

Next anchor: T+60d in 8d

Last close $83.01 (close Jun 8) · -5.70% from $78.53 entry (call sign-flipped)

Entry anchored
Mar 24, 03:59 PM ET
via Databento tick

T+1d

-0.14%

call +0.14% · α -1.63%

$78.42

settled 3mo ago

T+5d

+7.27%

call -7.27% · α -7.51%

$84.24

settled 2mo ago

T+20d

+12.43%

call -12.43% · α -4.57%

$88.29

settled 7w ago

T+60d

—

call — · α —

—

in 8d

Price Chart

Loading chart...

Executive Summary

Apogee Therapeutics priced an underwritten public offering of 5,000,000 shares at $70.00 per share, raising approximately $350 million in gross proceeds. The company also granted underwriters a 30-day option to purchase up to an additional 750,000 shares. The offering is expected to close on March 26, 2026, subject to customary conditions.

Key Financial Metrics

Deal Value

$350.0M

Actionable Insight

Traders should anticipate near-term share price pressure due to dilution from the new issuance, especially given recent insider selling. Monitor for exercise of the underwriters' option, which would increase dilution. Use of proceeds may provide insight into pipeline development timelines.

Key Facts

Apogee Therapeutics is offering 5,000,000 shares of common stock at $70.00 per share.
Gross proceeds from the offering are expected to be approximately $350 million.
Underwriters have a 30-day option to purchase up to an additional 750,000 shares.
The offering is expected to close on March 26, 2026, subject to customary closing conditions.
Jefferies, TD Cowen, Stifel, and Guggenheim Securities are joint book-running managers.

Financial Impact

$350 million in gross proceeds before expenses; potential for up to $402.5 million if underwriters exercise full option (750,000 additional shares at $70).

dilutioncashequity

Risk Factors

Significant equity dilution for existing shareholders.
Potential downward pressure on stock price post-offering due to increased supply and recent insider selling.
Forward-looking statements about clinical programs are speculative and subject to development risks.

Market Snapshot

Exchange

Nasdaq

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3261899

19 reports for APGE

T+1T+5T+20T+60

67% Hit rate 6 of 9 directional calls best @ T+20▲ +14.66%Mar 23, 2026

Filters

Reports for APGE — sortable, filterable
	Type				Now
May 27, 2026 13d ago	8-K BULLISH ★ 7/10	$77.75 $78.71	▲ +1.23%	▲ +0.03%	$83.01 (+6.77%)
May 27, 2026 13d ago	8-K BULLISH ★ 7/10	$77.75 $78.71	▲ +1.23%	▲ +0.03%	$83.01 (+6.77%)
May 27, 2026 13d ago	Press Release BULLISH ★ 7/10	$77.75 $78.71	▲ +1.23%	▲ +0.03%	$83.01 (+6.77%)
May 27, 2026 13d ago	Press Release BULLISH ★ 8/10	$77.75 $78.71	▲ +1.23%	▲ +0.03%	$83.01 (+6.77%)
May 26, 2026 14d ago	Press Release NEUTRAL ★ 6/10	$77.75 $78.71	▲ +1.23%	▲ +0.03%	$83.01 (+6.77%)
May 16, 2026 25d ago	Insider Cluster NEUTRAL ★ 3/10	$78.75 $82.81	▲ +5.16%	▲ +3.54%	$83.01 (+5.41%)
May 13, 2026 27d ago	144 NEUTRAL ★ 2/10	$83.94 $81.39	▼ −3.04%	▼ −2.90%	$83.01 (−1.11%)
May 11, 2026 29d ago	8-K BULLISH ★ 7/10	$84.60 $78.75	▼ −6.91%	▼ −6.83%	$83.01 (−1.88%)
May 11, 2026 29d ago	Press Release BULLISH ★ 7/10	$84.60 $78.75	▼ −6.91%	▼ −6.83%	$83.01 (−1.88%)
May 1, 2026 5w ago	Insider Cluster NEUTRAL ★ 2/10	$80.75 $83.03	▲ +2.82%	▲ +0.48%	$83.01 (+2.80%)

US Market Status

Market Closed — Opens in 7h 19m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access